Cel-Sci (CVM) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Metagenomi Therapeutics (MGX) has outperformed Cel-Sci (CVM) over the past year, losing 66.6% versus a loss of 79.1%. Cel-Sci is the larger company by market cap ($37.5 million vs $37.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CVM | MGX |
|---|---|---|
| Share price | $2.13 | $0.9847 |
| Market cap | $37.46M | $37.20M |
| 1-day change | -22.26% | -4.40% |
| YTD return | -59.51% | -39.22% |
| 1-year return | -79.12% | -66.62% |
| 5-year return | -99.32% | — |
| EPS (TTM) | $-1.69 | $-2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.62 | $3.95 |
| 52-week low | $0.89 | $0.96 |
| Distance from 52-week high | -79.94% | -75.07% |
| Average volume | 236.35K | 153.89K |
| Shares outstanding | 17.59M | 37.78M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGX has outperformed CVM by 12.5 percentage points over the past year.
CVM vs MGX FAQ
Which is bigger, Cel-Sci or Metagenomi Therapeutics?
Cel-Sci (CVM) is larger, with a market capitalization of $37.46M compared with $37.20M for Metagenomi Therapeutics (MGX).
Which stock has performed better over the past year, CVM or MGX?
MGX returned -66.62% over the past 12 months, compared with -79.12% for CVM (price return, excluding dividends). Past performance does not predict future results.
Are Cel-Sci and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.